Literature DB >> 27112173

Ranking Differential Drug Activities from Dose-Response Synthetic Lethality Screens.

Rajarshi Guha1, Lesley A Mathews Griner1, Jonathan M Keller1, Xiaohu Zhang1, David Fitzgerald2, Antonella Antignani2, Ira Pastan2, Craig J Thomas1, Marc Ferrer3.   

Abstract

Synthetic lethal screens are used to discover new combination treatments for cancer. In traditional high-throughput synthetic lethal screens, compounds are tested at a single dose, and hit selection is based on threshold activity values from the variance of the efficacy of the compounds tested. The limitation of the single-dose screening for synthetic lethal screens is that it does not allow for the robust detection of differential activities from compound collections with a broad range of potencies and efficacies. There is therefore a need to develop screening approaches that enable the identification of compounds with synthetic lethal effects based on changes in both potency and efficacy. Here we describe the implementation of a dose response-based synthetic lethal screen to find drugs that enhance or mitigate the cytotoxic effect of an immunotoxin protein (HA22). We developed a data analysis framework for the selection of compounds with enhancing or mitigating cytotoxic activities based on the use of dose-response parameters. The data analysis framework includes an ensemble ranking approach that allows the use of multiple dose-response parameters in a nonparametric fashion. Quantitative high-throughput screening (HTS) enables the identification of compounds with synthetic lethal activity not identified by single-dose HTS.
© 2016 Society for Laboratory Automation and Screening.

Entities:  

Keywords:  immunotoxin; qHTS; ranking; synthetic lethal screen

Mesh:

Substances:

Year:  2016        PMID: 27112173      PMCID: PMC7876566          DOI: 10.1177/1087057116644890

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  23 in total

Review 1.  A lethal combination for cancer cells: synthetic lethality screenings for drug discovery.

Authors:  Elisa Ferrari; Chiara Lucca; Marco Foiani
Journal:  Eur J Cancer       Date:  2010-08-17       Impact factor: 9.162

2.  Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries.

Authors:  James Inglese; Douglas S Auld; Ajit Jadhav; Ronald L Johnson; Anton Simeonov; Adam Yasgar; Wei Zheng; Christopher P Austin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-24       Impact factor: 11.205

Review 3.  Immunotoxin therapy of cancer.

Authors:  Ira Pastan; Raffit Hassan; David J Fitzgerald; Robert J Kreitman
Journal:  Nat Rev Cancer       Date:  2006-07       Impact factor: 60.716

4.  Systematic assessment of analytical methods for drug sensitivity prediction from cancer cell line data.

Authors:  In Sock Jang; Elias Chaibub Neto; Juistin Guinney; Stephen H Friend; Adam A Margolin
Journal:  Pac Symp Biocomput       Date:  2014

5.  Metrics other than potency reveal systematic variation in responses to cancer drugs.

Authors:  Mohammad Fallahi-Sichani; Saman Honarnejad; Laura M Heiser; Joe W Gray; Peter K Sorger
Journal:  Nat Chem Biol       Date:  2013-09-08       Impact factor: 15.040

6.  Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.

Authors:  Robert J Kreitman; Martin S Tallman; Tadeusz Robak; Steven Coutre; Wyndham H Wilson; Maryalice Stetler-Stevenson; David J Fitzgerald; Robert Lechleider; Ira Pastan
Journal:  J Clin Oncol       Date:  2012-02-21       Impact factor: 44.544

7.  Inconsistency in large pharmacogenomic studies.

Authors:  Benjamin Haibe-Kains; Nehme El-Hachem; Nicolai Juul Birkbak; Andrew C Jin; Andrew H Beck; Hugo J W L Aerts; John Quackenbush
Journal:  Nature       Date:  2013-11-27       Impact factor: 49.962

8.  HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.

Authors:  Sookhee Bang; Satoshi Nagata; Masanori Onda; Robert J Kreitman; Ira Pastan
Journal:  Clin Cancer Res       Date:  2005-02-15       Impact factor: 12.531

Review 9.  Immunotoxins for leukemia.

Authors:  Alan S Wayne; David J Fitzgerald; Robert J Kreitman; Ira Pastan
Journal:  Blood       Date:  2014-02-27       Impact factor: 22.113

10.  Systematic discovery of multicomponent therapeutics.

Authors:  Alexis A Borisy; Peter J Elliott; Nicole W Hurst; Margaret S Lee; Joseph Lehar; E Roydon Price; George Serbedzija; Grant R Zimmermann; Michael A Foley; Brent R Stockwell; Curtis T Keith
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-10       Impact factor: 11.205

View more
  2 in total

1.  Chemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion Proteins.

Authors:  Antonella Antignani; Lesley Mathews Griner; Rajarshi Guha; Nathan Simon; Matteo Pasetto; Jonathan Keller; Manjie Huang; Evan Angelus; Ira Pastan; Marc Ferrer; David J FitzGerald; Craig J Thomas
Journal:  PLoS One       Date:  2016-08-24       Impact factor: 3.240

2.  A Comparative Study of Target Engagement Assays for HDAC1 Inhibitor Profiling.

Authors:  Rosita R Asawa; Alexey Zakharov; Taylor Niehoff; Ata Chitsaz; Ajit Jadhav; Mark J Henderson; Anton Simeonov; Natalia J Martinez
Journal:  SLAS Discov       Date:  2019-10-29       Impact factor: 3.341

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.